Summary
In adults, the haemolytic-uraemic syndrome (HUS) is associated with probable causative factors in the minority of all cases. Cytotoxic drugs are one of these potential causative agents. Although metastatic cancer by itself is a recognized risk-factor for the development of HUS, therapy with mitomycin-C, with cis-platinum, and with bleomycin carries a significant, albeit extremely small, risk for the development of HUS, compared with all other cytotoxic drugs. Gemcitabine is a novel cytotoxic drug with promising activity against pancreatic adenocarcinoma. We are reporting on one patient with metastatic duodenal papillary carcinoma developing HUS while on weekly gemcitabine therapy. The presenting features in this patient were non-cardiac pulmonary oedema, renal failure, thrombocytopenia and haemolytic anaemia. The diagnosis of HUS was made on the day of admission of the patient to this institution. Upon aggressive therapy, including one single haemodialysis and five plasmaphereses, the patient recovered uneventfully, with modestly elevated creatinine-values as a remnant of the acute illness. Re-exposure to gemcitabine 6 months after the episode of HUS instituted for progressive carcinoma, thus far has not caused another episode of HUS.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Anderson, H., Lund, B., Bach, F., Thatcher, N., Walling, J. & Hansen, H. H. (1994). Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 12: 1821–1826.
Brain, M. C., Dacie, J. V. & Hourihane, O. B. (1962). Microangiopathic hemolytic anemia: the possible role of vascular lesions in pathogenesis. Br J Haematol 8: 358–364.
Brodowicz, T., Breiteneder, S., Witschke, C. & Zielinski, C. C. (1997). Gemcitabine-induced hemolytic uremic syndrome: a case report (letter). J Natl Cancer Inst 89: 1895–1896.
Casper, E. S., Green, M. R., Kelsen, D. P., Heelan, R. T., Brown, T. D., Flombaum, C. D., Trochanowski, B. & Tarassoff, P. G. (1994). Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 12: 29–34.
Conlon, P. J., Howell, D. N., Macik, G., Kovalik, E. C. & Smith, S. R. (1995). The renal manifestations and outcome of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome in adults. Nephrol Dial Transplant 10: 1189–1193.
Cortes-Funes, H., Martin, C., Abratt, R. & Lund, B. (1997). Safety profile of gemcitabine, a novel anticancer agent, in non-small-cell lung cancer. Anticancer Drugs 8: 582–587.
Crocker, J. & Jones, E. L. (1983). Haemolytic-uraemic syndrome complicating long-term mitomycin C and 5-fluorouracil therapy for gastric carcinoma. J Clin Pathol 36: 24
DeWit, M., Weh, H. J. & Hossfeld, D. K. (1996). Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Med Welt 47: 528–532.
Dobbie, M., Hofer, S., Oberholzer, M. & Herrmann, R. (1998). Veno-occlusive disease of the liver induced by gemcitabine (letter). Ann Oncol 9: 681
Furlan, M. (1996). Von Willebrand factor: molecular size and functional activity. Ann Hematol 72: 341–348.
Green, M. R. (1996). Gemicitabine safety overview. Semin Oncol 23(suppl 10): 32–35.
Groff, J. A., Kozak, M., Boehmer, J. P., Demko, T. M. & Diamond, J. R. (1997). Endotheliopathy: a continuum of hemolytic uremic syndrome due to mitomycin therapy. Am J Kidney Dis 29: 280–284.
Gulati, S. C., Sordillo, P. & Kempin, S., et al (1980). Microangiopathic hemolytic anemia observed after treatment of epidermoid carcinoma with mitomycin C and 5-fluorouracil. Cancer 45: 2252
Keller, F., Schwarze, H. & Schwarz, A. (1994). Clinical management of hemolytic-uremic syndrome and thrombotic-thrombocytopenic purpura. Wien Klin Wochenschr 106: 603–607.
Kienast, J. & Schmitz, G. (1990). Flow cytometric analysis of thiazole orange uptake by platelets: a diagnostic aid in the evaluation of thrombocytopenic disorders. Blood 75: 116–121.
Matsumae, T., Takebayashi, S. & Naito, S. (1996). The clinico-pathological characteristics and outcome in hemolytic-uremic syndrome of adults. Clin Nephrol 45: 153–162.
Nordstrom, B. & Strang, P. (1993). Microangiopathic hemolytic anemias (MAHA) in cancer. A case report and review. Anticancer Res 13: 1845–1850.
Sens, Y. A. S., Miorin, L. A., Silva, H. G. C., Malheiros, DMAC, Filho, D. M. & Jabur, P. (1997). Acute renal failure due to hemolytic-uremic syndrome in adult patients. Renal Fail 19: 279–282.
Streiff, M. & Bell, W. R. (1993). Thrombotic thrombocytopenic purpura – hemolytic uremic syndrome. Curr Opin Hematol 1: 274
Tonato, M., Mosconi, A. M. & Martin, C. (1995). Safety profile of gemcitabine. Anticancer Drugs 6(suppl 6): 27–32.
Verwey, J., De Vries, J. & Pinedo, H. M. (1987). Mitomycin C-induced renal toxicity, a dose-dependent side effect? Eur J Cancer 23: 195
Zeigler, Z. R., Rosenfeld, C. S., Andrews, III D. F., Nemunaitis, J., Raymond, J. M., Shadduck, R. K., Kramer, R. E., Gryn, J. F., Rintels, P. B., Besa, E. C. & George, J. N. (1996). Plasma von Willebrand factor antigen (vWF:AG) and thrombomodulin (TM) levels in adult thrombotic thrombocytopenic purpura/hemolytic uremic syndromes (TTP/HUS) and bone marrow transplant-associated microangiopathy (BMT-TM). Am J Hematol 53: 213–220.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Serke, S., Riess, H., Oettle, H. et al. Elevated reticulocyte count – a clue to the diagnosis of haemolytic-uraemic syndrome (HUS) associated with gemcitabine therapy for metastatic duodenal papillary carcinoma: a case report. Br J Cancer 79, 1519–1521 (1999). https://doi.org/10.1038/sj.bjc.6690242
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690242
Keywords
This article is cited by
-
Pediatric onco-nephrology: time to spread the word
Pediatric Nephrology (2021)
-
Hemolytic uremic syndrome following prolonged gemcitabine therapy: report of four cases from a single institution
Annals of Hematology (2005)